ORIGINAL RESEARCH article

Front. Mol. Neurosci., 17 October 2022

Sec. Brain Disease Mechanisms

Volume 15 - 2022 | https://doi.org/10.3389/fnmol.2022.954167

Imbalance between the function of Na+-K+-2Cl and K+-Cl impairs Cl homeostasis in human focal cortical dysplasia

  • 1. Guangzhou Laboratory, Guangzhou, China

  • 2. Beijing Tiantan Hospital, Capital Medical University, Beijing, China

  • 3. Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China

  • 4. Neuroelectrophysiological Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China

  • 5. Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

  • 6. Department of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China

  • 7. Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China

  • 8. Department of Pharmacology, Zhejiang University City College, Hangzhou, China

Abstract

Objective:

Altered expression patterns of Na+-K+-2Cl (NKCC1) and K+-Cl (KCC2) co-transporters have been implicated in the pathogenesis of epilepsy. Here, we assessed the effects of imbalanced NKCC1 and KCC2 on γ-aminobutyric acidergic (GABAergic) neurotransmission in certain brain regions involved in human focal cortical dysplasia (FCD).

Materials and methods:

We sought to map a micro-macro neuronal network to better understand the epileptogenesis mechanism. In patients with FCD, we resected cortical tissue from the seizure the onset zone (SOZ) and the non-seizure onset zone (non-SOZ) inside the epileptogenic zone (EZ). Additionally, we resected non-epileptic neocortical tissue from the patients with mesial temporal lobe epilepsy (MTLE) as control. All of tissues were analyzed using perforated patch recordings. NKCC1 and KCC2 co-transporters expression and distribution were analyzed by immunohistochemistry and western blotting.

Results:

Results revealed that depolarized GABAergic signals were observed in pyramidal neurons in the SOZ and non-SOZ groups compared with the control group. The total number of pyramidal neurons showing GABAergic spontaneous postsynaptic currents was 11/14, 7/17, and 0/12 in the SOZ, non-SOZ, and control groups, respectively. The depolarizing GABAergic response was significantly dampened by the specific NKCC1 inhibitor bumetanide (BUM). Patients with FCD exhibited higher expression and internalized distribution of KCC2, particularly in the SOZ group.

Conclusion:

Our results provide evidence of a potential neurocircuit underpinning SOZ epileptogenesis and non-SOZ seizure susceptibility. Imbalanced function of NKCC1 and KCC2 may affect chloride ion homeostasis in neurons and alter GABAergic inhibitory action, thereby contributing to epileptogenesis in FCDs. Maintaining chloride ion homeostasis in the neurons may represent a new avenue for the development of novel anti-seizure medications (ASMs).

Introduction

Focal cortical dysplasia (FCD) is a common cause of refractory epilepsy (). Histological features have shed light on the cytoarchitectural differences and underpinning developmental pathogenic mechanisms allowing for a more detailed categorization of FCD. However, from a functional perspective, the electrophysiological changes corresponding to these pathological changes and precise epileptogenic mechanisms of FCD remain unknown ().

Epilepsy results from an imbalance between excitatory and inhibitory synaptic transmission in the brain (). Previous studies have documented decreased expression of γ-aminobutyric acid (GABA) receptor subunits, reduced γ-aminobutyric acidergic (GABAergic) interneuron, and decreased spontaneous postsynaptic GABA currents in pyramidal neurons. This may underpin the epileptogenic mechanisms of FCD (; ; ). FCD patients with epilepsy typically exhibit resistance to conventional anti-seizure medications (ASMs), especially GABAA receptor agonists; this remains a clinical challenge. Recent studies have demonstrated that the Na+-K+-2Cl (NKCC1) and K+-Cl (KCC2) cotransporters alter GABAergic inhibitory function by regulating intracellular chloride concentration ([Cl]i) (; ). Histological and molecular studies have revealed altered expression and distribution patterns of NKCC1 and KCC2 in the dysplastic neurons of patients with FCD exhibiting epilepsy (; ; ). In addition, bumetanide (BUM), a specific blocker of NKCC1, has been reported to exhibit antiepileptic effects in several preclinical and clinical studies (; ; ; ; ). This suggests that the expression and function changes in the chloride co-transporter play important roles in epileptogenesis. However, electrophysiological studies of the functional alterations underlying these changes remain limited. reported the depolarized equilibrium potential of GABA (EGABA) and prominent GABAA receptor (GABAAR)-mediated spontaneous and evoked depolarizing responses in pediatric patients with severe FCD exhibiting epilepsy. demonstrated that the abnormal function and expression of the chloride transporter in neurons of patients with FCD exhibiting epilepsy may lead to the paradoxical depolarization of pyramidal neurons. However, these studies have inherent limitations, such as inevitable disputed [Cl]i caused by whole-cell recordings or the lack of intracellular recordings.

At the macroscopic level, based on electrocorticography (ECoG) data defined the epileptogenic zone (EZ) as the area of the cortex necessary for the generation of recurrent seizures that needs to be removed to achieve seizure freedom. Recently, under diverse macroscopic diagnostic tools, different cortical zones have been conceptualized, such as the seizure onset zone (SOZ), which has been found to be characterized by anomalous EEG signals compared with the surrounding tissues (; ). Although the temporal dynamics of epileptiform synchronization and epileptogenic networks are well described at the macroscopic level, the key features at the cellular and microcircuit levels cannot be captured by macroscopic evaluation. Therefore, little remains known about the microscopic characteristics and network changes of the EZ (). Clinicians were determined to gain a comprehensive understanding of epileptic mechanisms through multi-scale evaluations. Therefore, in this study, we selected the SOZ and non-seizure onset zone (non-SOZ) in the EZ of patients with FCD exhibiting epilepsy to assess disease-related changes at the cellular and microcircuit levels.

This study sought to compare the detailed electrophysiological characterization of GABAergic neurotransmission in pyramidal neurons in the SOZ and non-SOZ inside the EZ of patients with FCD with non-epileptic temporal neocortex and to correlate these features with the patterns of NKCC1 and KCC2. We probed whether depolarizing GABAergic action caused by the imbalanced function of NKCC1 and KCC2 cotransporters would perturb chloride ion homeostasis in neurons and contribute to the generation and propagation of epilepsy in patients with FCD.

Materials and methods

Patient selection and cortical tissue acquisition

In this study, 30 patients with intractable epilepsy were enrolled at Xuanwu Hospital of Capital Medical University from June 2018 to December 2019. Following a standardized preoperative evaluation, all patients underwent surgery to remove the EZ. Neocortical tissues were obtained from 20 patients with FCD and epilepsy. In addition, 10 patients with mesial temporal lobe epilepsy (MTLE) were chosen as the control group because of their relatively non-epileptic neocortical tissue, as suggested by previous studies (; ). The temporal neocortex of these patients with MTLE was characterized by no obvious structural aberration and minimal epileptic discharge based on intraoperative ECoG recording. The detailed clinical information and pathological characteristics of the enrolled patients are summarized in Table 1. Our research protocol was approved by the Medical Ethics Committee of Xuanwu Hospital, Capital Medical University. All patients were well informed about the study, and consents were obtained from them.

TABLE 1

Patient/Sex/AgeHistologyOnset age; frequencySz typesASMs, n; NameEEGMRI; PETSurgeryRegionsGroups
FCD
1/M/18.5 yearsFCD Ia15 years; 2–3 Sz/dayFocal impaired awareness seizure2; OXC, LEVAbnormal spikes in RTNormal MRI; hypometabolism in RTRT + RI cortectomyRITSOZ
2/M/34 yearsFCD Ia7 years; NAFocal impaired awareness seizure, GTCS2; CBZ, VPAAbnormal spikes in LTNormal MRI; hypometabolism in LTLT lesion- ectomy after SEEGLTSOZ non-SOZ
3/F/22.1 yearsFCD IIa10 years; NAFocal aware/impaired awareness seizureNAAbnormal spikes in RFAbnormal signals in RA; hypometabolism in RF and RTRF cortectomy after SEEGRMFSOZ
4/F/28.8 yearsFCD IIa9 years; 1 Sz/several daysFocal aware/impaired awareness seizure, GTCS2; LEV, LTGRhythmic posterior RMF spikes and wavesNA; hypometabolism in RF and RITRF and RT lesionectomyRSFSOZ
5/M/31 yearsFCD IIa2 years; 10 Sz/monthFocal impaired awareness seizure2; OXC, VPAAbnormal spikes in LFMild LH swelling; hypometabolism in LF, LT, and LPLF, LT, LH lesionectomy after SEEGLMFSOZ
6/F/7 yearsFCD IIb4 years; 2 Sz/dayFocal aware seizure2; OXC, LEVAbnormal spikes in LFNALF lesion-ectomyLMFSOZ
7/F/11.9 yearsFCD IIIa5 years; 1–2 Sz/weekFocal impaired awareness seizure3; VPA, OXC, CBZAbnormal spikes in LTLH abnormal signals; hypo-metabolism in LT, LP, LOLATL after SEEGLTPSOZ
8/M/31.3 yearsFCD IIIa24 years; 3–5 Sz/monthAS2; LTG, VPARhythmic LT spikes and slow wavesBilateral mild HS; hypometabolism in LT, LHMesial LT lobectomy after SEEGLTPSOZ
9/M/27.6 yearsFCD IIIb + CG9 years; 2 Sz/monthFocal impaired awareness seizure2; CBZ, VPARP, RT slow wavesEncephalomalacia foci in RP; NART + RP lesionectomy after SEEGRIPSOZ
10/M/11.1 yearsCD2 years; NAFocal impaired awareness seizure, GTCS, SENAAbnormal spikes in RF, RMTR cerebral hemisphere malformation; NALesion-ectomy + hemispherectomyRTSOZ
11/F/12 yearsCD2 years; >2 Sz/six monthsFocal impaired awareness seizure, GTCS2; OXC, LEVRhythmic RP, RO, RT, central gyrus spikes and wavesRSF, RP G/W matter blur-ring; hypometabolism in RSP, RITLesionectomyRTSOZ
12/F/35 yearsFCD Ia20 years; 1–2 Sz/dayFocal impaired awareness seizure1; CBZRhythmic RF, RT spikesHypersignal in RH; hypo-metabolism in RT, RHRATL after SEEGRMTnon-SOZ
13/M/22.8 yearsFCD Ib11 years; >10 Sz/monthfocal impaired awareness seizure2; CBZ, PBAbnormal spikes in RTFLAIR hyper-signal in RH; hypometabo-lism in RTRATLRMTnon-SOZ
14/M/24.3 yearsFCD IIa10 years; 1–2 Sz/dayFocal impaired awareness seizure, GTCS2; TPA, CBZRF spikes and wavesNormal MRI; hypometabo-lism in RFRF cortectomyRSFnon-SOZ
15/F/15 yearsFCD IIb5 years; 10–20 Sz/monthFocal impaired awareness seizure, GTCS2; VPA, TPMRhythmic LF, LT spikes, and slow wavesFLAIR hypersignal in LF; NALF + LCC cortectomy after SEEGLSFnon-SOZ
16/F/12 yearsFCD IIb5 years; 4 Sz/weekFocal impaired awareness seizure2; OXC, LEVRhythmic RT spikes and slow wavesRT abnormal signals; NART cortectomy after SEEGRTnon-SOZ
17/F/11 yearsFCD IIb6 years; 1–2 Sz/weekFocal impaired awareness seizure4; OXC, VPA, LTG, CLZSpikes and slow waves in LF, central area and LTLACC G/W blurring; hypometabo-lism in LF and LPLF + LCC cortectomy after SEEGLSFnon-SOZ
18/M/26 yearsFCD IIIb + CG1 year; 1 Sz/monthFocal impaired awareness seizure2; CBZ, VPAAbnormal spikes in RFEncephalomalacia in RF and RIRF cortectomy after SEEGRIFnon-SOZ
19/M/31.7 yearsCD29 years; 2–3 Sz/dayGTCS1; CBZRT and RF slow wavesR cerebral hemisphere malformation; hypometa-bolism in RT, RH, and RIFRF + RT cortectomyRTnon-SOZ
20/F/34.1 yearsCD13 years; 4–5 Sz/weekFocal aware/impaired awareness seizure, GTCS1; CBZRhythmic RF and RT waves and spikes.RHS and RF G/W blurring; hypometabo-lism in RF and posterior RITRF + RT cortectomy after SEEGRIFnon- SOZ
Con
21/F/30 yearsHS23 years; 1–2 Sz/dayFocal impaired awareness seizure2;LEV, VPART spike (or sharp) slow waveRHS; hypo-metabolism in RTRATLRTPCon
22/F/21 yearsHS (WHO I)1 year; 4–5 Sz/monthFocal impaired awareness seizure4; LTP, PB, VPA, CBZLT spike (or sharp) slow waveLHS; hypo-metabolism in LHLATLLTPCon
23/F/32 yearsHS (WHO I)2 years; NAFocal impaired awareness seizure GTCS3; PB, LTG, CBZRhythmic LT spikesLHS; hypo-metabolism in LT and LHLATLLTPCon
24/F/33 yearsHS26 years; NAFocal impaired awareness seizure GTCS2; OXC, TPMRhythmic RH spikesRHS; hypo-metabolism in RHRATLRTPCon
25/M/48.5 yearsHS (WHO I)30 years; 1–3 Sz/dayFocal impaired awareness seizure GTCSNALT slow waves and spikesLT abnormal signals; NALATLLTPCon
26/M/45.7 yearsGG18 years; >3 Sz/weekFocal impaired awareness seizure, GTCS2; CBZ, LEVRhythmic RT spikesHypersignal in RH; hypometabolism in RMTRATLRTPCon
27/M/27 yearsHGM16 years; 1–2 Sz/weekFocal impaired awareness seizure3; TPM, VPA, CBZRhythmic RT spikes and slow wavesNormal MRI; hypometabolism in RP and RTRATLRTPCon
28/M/39.3 yearsHGM24 years; 1–2 Sz/dayFocal impaired awareness seizure, GTCS1;OXCAbnormal spikes in LTBilateral mild HS; NALATLLTPCon
29/F/38 yearsHS23 years; 3–4 Sz/dayFocal aware/impaired awareness seizure1;CBZAbnormal spikes in LTReduced LT; hypometabolism in LP, LF, LTLATLLTCon
30/M/6 yearsCG4 years; 3–4 Sz/dayFocal aware/impaired awareness seizure1;VPAAbnormal spikes in LTReduced volume of LH; NALATLLTCon

Patients characteristics.

ACC, anterior cingulate; ASM, antiseizure medicine; AS, atypical seizure; ATL, anterior temporal lobectomy; CBZ, carbamazepine; CG, cicatricial gyrus; CLZ, clonazepam; EEG, electroencephalography; F, female; FCD, focal cortical dysplasia; F, frontal lobe; GTCS, generalized tonic-clonic seizures; GG, ganglioglioma; G/W, gray/white; H, hippocampus; HGM: heterotopic gray matter; HS, hippocampal sclerosis; I, insular; L, left; LCM, lacosamide; LEV, levetiracetam; IF, inferior frontal gyrus; LRZ, lorazepam; LTG, lamotrigine; M, male; MF, middle frontal lobe; MT, middle temporal gyrus; NA, information not available; O, occipital lobe; OXC, oxcarbazepine; PB, Phenobarbital; PHT, phenytoin; RA, right amygdaloid nucleus; PPA, para-hippocampal place area; RP, right parietal lobe; RT, right temporal lobe; SE, status epilepticus; SF, superior frontal gyrus; Sz, seizure(s); T, temporal lobe; TP, temporal pole; TPM, topiramate; VPA, valproic acid.

Each patient recruited in the study underwent standardized preoperative evaluation procedures to delineate the EZ and locate the SOZ, including detailed clinical history, neurological examinations, video-electroencephalographic recordings (vEEG), neuropsychological examinations, and neuroimaging studies, etc. Neuroimaging studies include high-resolution magnetic resonance imaging (MRI, 3T), magnetoencephalography, and 18-fluorodeoxyglucose positron emission tomography (FDG-PET). As mentioned above, defined the EZ as the area of cortex that is indispensable for the generation of epileptic seizures. An integral component for the delineation of the EZ is the seizure onset zone (SOZ): the area of cortex that initiates clinical seizures as determined predominantly by intracranial investigations. Inside the EZ, two blocks of neocortical tissue (1 cm × 1 cm × 1 cm) were defined as SOZ and non-SOZ. However, there is currently no clear definition of “non-SOZ.” In this study, SOZ is confirmed as the area of cortex that initiates clinical seizures by combining presurgical intracranial investigations and symptomatology (Figure 1A, electrode B). For the other area expect SOZ in the surgical resection, as our previous study, we choose “non-SOZ” as one of brain tissue which is also located in the area to be excised but showing the least abnormal electrophysiological recordings under subdural recording (Figure 1B; ).

FIGURE 1

Given that the brain tissue is taken during surgery, the surgeon cannot cut off the blood supply in order to keep the brain tissue alive before collecting the brain tissue. When we collected the first two samples (SOZ and non-SOZ) from the first patient, it was shown that collecting two brain tissues at the same time would cause more serious bleeding which did inevitable damages to the patient. Therefore, from the second patient, we adopted a double-blind and random sampling method, and each patient randomly collected one piece of brain tissue. All patients with FCD were confirmed by a postoperative histological examination (Figure 1C). In summary, we divided our experiment into three groups: the SOZ, non-SOZ, and control groups.

Brain tissue slice preparation

After being obtained in the operating room, neocortical tissues were immediately placed into an ice-cooled and oxygenated (95% O2 and 5% CO2) cutting solution containing 220 mM sucrose, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 0.5 mM CaCl2, 7 mM MgCl2, and 10 mM D-glucose (pH 7.4; osmolarity maintained at 340 mOsm/kg), and transferred to our electrophysiological laboratory within 5–10 min. Subsequently, meninges and blood clots were gently removed, and 400 μm neocortical transverse slices were cut using a vibratome (VT 1000S; Leica Microsystems, Wetzlar, Germany) and incubated in oxygenated (95% O2 and 5% CO2) artificial cerebrospinal fluid (ACSF) containing (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 2 MgCl2, and 10 D-glucose (pH 7.3; osmolarity maintained at 300–310 mOsm/kg) at room temperature for at least 1 h before recording.

Perforated patch-clamp recording and data analysis

Following incubation, the brain slices were submerged in a recording chamber perfused with oxygenated ACSF at a rate of 2–2.5 mL/min at room temperature. Perforated patch-clamp recordings were performed on pyramidal neurons in the neocortex and viewed under an infrared differential interference contrast microscope with a Nikon 40 water immersion lens (ECLIPSE FN1, Nikon Corp., Tokyo, Japan). Recordings were performed in layers III and IV in the non-SOZ and control groups. In the SOZ group, in which the lamina was not clearly defined, layers III and IV were generally located according to the non-SOZ lamina in the middle region of the dysplastic cortex (Figure 2A). Pyramidal neurons were identified based on their triangular-shaped cell bodies and relatively simple axons and were confirmed by electrophysiological recordings as displaying longer action potential (AP) half-widths and lower peak AP frequency (). Recording electrodes (resistance, 4–6 MΩ) were prepared from borosilicate glass capillaries (B15014F, Vital Sense Scientific Instruments Co., Ltd., Wuhan, China) using a horizontal pipette puller (P-1000 Next Generation Micropipette Puller, Sutter Instrument, CA, USA). The pipette solution contained (in mM) 135 KCl, 10 HEPES, 0.5 CaCl2, 2 MgCl2, and 5 EGTA (pH 7.3 adjusted with KOH; osmolarity maintained at 290–300 mOsm/kg). Gramicidin was stocked at an initial concentration of 16 mg/ml and then diluted with pipette solution to reach a final concentration of 80 μg/ml. The electrode tip and barrel were backfilled with pipette solution and gramicidin-containing pipette solution, respectively. Following the formation of a tight seal and after the series resistance (Rs) decreased and stabilized at 30–110 MΩ, we started recording. Recordings were ended when a rapid decrease in Rs and a “leak-like” current were observed, indicating that the cell had entered the conventional whole-cell configuration by rupture of the membrane seal. The resistance and capacitance of the pipette have been compensated. Liquid junction potential was not corrected.

FIGURE 2

We first recorded the resting membrane potential (Vm), membrane conductance, and firing properties to identify pyramidal neurons in the current-clamp mode. Next, we recorded spontaneous excitatory postsynaptic currents (sEPSCs) for 3 min at a holding potential of −70 mV in the voltage-clamp mode. Subsequently, we acquired pharmacologically isolated GABAergic sPSCs by applying 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 μM) and DL-2-amino-5-phosphonopentanoic acid (DL-AP5, 100 μM) to block α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors. BUM (10 μM) was then added to assess its effects on GABAergic sPSCs. The sEPSCs were automatically detected at amplitude adjusted above the root 2 mean square noise level using Clampfit 10.5 (Molecular Devices, CA, USA). Cumulative amplitudes were calculated by summating amplitudes of all events within 180 s periods.

In this study, to probe the EGABA of pyramidal neurons, we first determined the neuronal firing patterns in response to depolarizing current injections prior to perfusion with tetrodotoxin. We applied GABA in the chamber with a pulsed fashion immediately during the ramp test. A hand-made fast drug delivery systems was used to apply GABA (100 μM, containing: CGP 35348, 1 μM; TTX, 1 μM) from a pipette resting 10 –20 μm above the slice at the position of the recorded soma. The system enabled quick fluid changes with a speed of 1 ml/min and a diameter of about 20 μm for its tip. Voltage ramps −80 to + 10 mV over 100 ms applied from a holding potential of −70 mV in the absence and presence of GABA were used to determine EGABA. The membrane voltage at which the current traces, obtained in the presence and absence of GABA, crossed was measured as the apparent EGABA. Then, voltage ramps were repeated following the addition of BUM (10 μM). The membrane voltage at which the current traces, obtained in the presence and absence of BUM, crossed was measured as the apparent EBUM. In addition, the driving force for GABA production (DFGABA = EGABA–Vm) was measured.

Immunohistochemistry

The brain tissue was fixed in 10% formalin and embedded in paraffin. Paraffin-embedded tissues were sectioned at 6 μm and heated in a microwave oven (60°C for 60 min). The sections were thereafter deparaffinized in xylene and rehydrated sequentially in graded concentrations of alcohol. Sections from the SOZ, non-SOZ, and control groups were probed with an anti-KCC2 antibody (Millipore, #07-432, Boston, MA, USA, 1:200) overnight at 4°C. The slides were then incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. Immunolabeling was visualized using the avidin-biotin conjugation method and 3,3′-diaminobenzidine. The sections were next counterstained with hematoxylin.

Immunofluorescence staining

Brain slices were post-fixed with 10% formalin, washed three times with PBS, incubated for 30 min with 0.3% Triton, and then blocked with 1% goat serum for 1 h to avoid binding of non-specific antibodies. Sections were then incubated at 4°C overnight with the following primary antibodies: anti-NKCC1 (Millipore, PA5-118800, Boston, MA, USA, 1:200), anti-NeuN (Sigma-Aldrich, St. Louis, MO, USA, MAB377, 1:200). Secondary antibodies conjugated to Alexa Fluor 488 or 594 (1:1,000; Invitrogen) were applied for 1.5 h at room temperature. Slides were mounted with Fluoroshield containing DAPI (Ab104139; Abcam) and observed with a confocal microscope (LSM710; Zeiss, Oberkochen, Germany).

Western blot analysis

Total protein was quantified using a BCA Protein Assay Kit (Solarbio, Beijing, China). Samples were electrophoresed on 5 and 10% Tris–HCl gels, transferred onto polyvinylidene difluoride membranes, and incubated with primary antibodies (anti-KCC2, Millipore, 1:1,000). GAPDH (mouse monoclonal IgG, CST, Danvers, MO, USA 1:5,000) was used as the reference protein. Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit IgG and anti-mouse IgG; LI-COR, USA) were used to bind the primary antibodies. The bands were visualized using a two-channel infrared (IR) scanner (Odyssey, NE, USA). Densitometric analysis of the protein signals was carried out using the ImageJ software (version 6.0; NIH, Bethesda, MD, USA). The target protein levels were normalized to internal control.

Statistical analysis

All data distributions were assessed with the Shapiro–Wilk test. For the normal distribution, data were analyzed using Student’s t-test or one-way ANOVA with post-hoc tests. Results were expressed as mean ± standard error of the mean (SEM), with significance set at p < 0.05. For the skewed distribution, analysis was carried out using the non-parametric Kruskal–Wallis test followed by Dunn’s multiple comparisons or Mann–Whitney U-test. Results were expressed as medians and interquartile range (IQR), with significance set at p < 0.05.

Results

Clinical information

First, we analyzed the clinical characteristics of the patients included in this study. No significant differences in the mean duration of epilepsy were observed across the groups. Briefly, the male/female ratio of patients with FCD exhibiting epilepsy enrolled in the study was 1:1, the mean duration of epilepsy being 13.5 ± 1.8 years and the average age at surgery being 22.9 ± 2.1 years old. The EZ in the FCD was localized in frontal (n = 9), temporal (n = 10), or posterior quadrants (n = 1).

Comparison of electrophysiological properties in pyramidal neurons among seizure the onset zone, non-seizure the onset zone, and control groups

Using perforated patch-clamp recording, we first compared the basic electrophysiological properties of pyramidal neurons across the three groups in the current-clamp mode. No significant differences were observed across the groups in terms of average Vm, cell capacitance (Cm), input resistance (RN), or membrane time constant (Table 2). No significant differences were observed across the pyramidal neurons of the three groups regarding the characteristics of the action potentials induced by the injection of a + 300 pA current (Figures 2B,C and Supplementary Figure 1).

TABLE 2

FCD (SOZ, N = 20)FCD (non-SOZ, N = 18)Control (N = 16)
RMP (mV)−74.4 (−64.1 to −78.3)−76.5 (−72.0 to −79.8)−73.1 (−69.9 to −78.1)
Cm (pF)109.3 (81.2 to 129.9)88.7 (83.25 to 104.8)99.1 (77.2 to 119.2)
RN (MΩ)226.2 ± 26.4189.4 ± 20.9229.9 ± 22.0
Time constant (ms)5.0 ± 0.54.2 ± 0.55.0 ± 0.4

Comparison of the intrinsic membrane properties of pyramidal neurons among different groups.

RMP, resting membrane potential; Cm, membrane capacitance; RN, input resistance. Values are reported as mean ± SEM; medians and interquartile range (IQR), with significance set at p < 0.05. There was no significant difference among three groups in the above parameters.

Next, we recorded the sEPSCs of pyramidal neurons in the SOZ, non-SOZ, and control groups held at −70 mV. The average frequency of sEPSCs on pyramidal neurons was significantly lower in the control group than in the SOZ group (median = 0.25 Hz, IQR = 0.1–0.28 Hz, n = 17 vs. median = 0.36 Hz, IQR = 0.22–0.85 Hz, n = 20, p = 0.02) and non-SOZ group (median = 0.53 Hz, IQR = 0.28–1.05 Hz, n = 16, p = 0.003). However, no significant difference was observed between the SOZ and non-SOZ groups. The median amplitude of sEPSCs on pyramidal neurons was not significantly different among the three groups. The decay time was smaller in the non-SOZ group (median = 17.02 ms, IQR = 15.95–18.54 ms) than in the control group (median = 23.11 ms, IQR = 19.61–47.29 ms, p = 0.0001) and the SOZ group (median = 19.73 ms, IQR = 18.62–31.47 ms, p = 0.02). In addition, no significant differences in the sEPSC rise time were observed across the groups (Figures 2D,E).

In a previous study, Talos et al. applied glutamatergic receptor antagonists to isolate and confirm the GABAergic components (GABAA receptor-mediated spontaneous postsynaptic currents, GABAAR-mediated sPSCs) with picrotoxin at a holding potential close to RMP in patients with tuberous sclerosis (). Based on their study’s results, we assessed the effects of GABAergic neurotransmission on sPSCs after blocking glutamatergic receptors to investigate the alterations in GABAergic neurotransmission in human dysplastic epileptic tissues. We first recorded sEPSCs in pyramidal neurons under normal ACSF perfusion in the SOZ, non-SOZ, and control groups, followed by the complete blockade of AMPA and NMDA receptors with CNQX and DL-AP5. Consistent with a previous study, under conditions of complete AMPA and NMDA receptor blockade, residual GABAAR-mediated sPSCs disappeared completely in the control group. However, GABAAR-mediated sPSCs remained present in the SOZ and non-SOZ groups, although they were significantly reduced (Figure 3A).

FIGURE 3

We assessed the effects of BUM, a NKCC1 blocker, on GABAAR-mediated sPSCs. We first probed how BUM would affect sPSCs by regulating neuronal action potentials. Results demonstrated that BUM did not change the frequency, peak amplitude, threshold, or half-width of the neuronal action potential (data not shown). We normalized GABAAR-mediated sPSCs before and after the application of BUM (10 μM). BUM reduced GABAAR-mediated sPSCs frequency (from 1 to 0.25; n = 10, p = 0.002) and cumulative amplitude (from 1 to 0.24, n = 10, p = 0.004) in FCD patients (Figure 3B). No significant effect of BUM was observed on GABAAR-mediated sPSCs amplitude (Figure 3B).

Features of γ-aminobutyric acidergic transmission

We found no GABAAR-mediated sPSCs on pyramidal neurons in the control group. However, GABAAR-mediated sPSCs were more common in neurons in the SOZ group (11/18, 61.11%) than in the non-SOZ (7/18, 38.89%). There was no significant difference in the frequency of GABAAR-mediated sPSCs (median = 0.08 Hz, IQR = 0.03–0.17 Hz, n = 11 vs. median = 0.07 Hz, IQR = 0.02–0.11 Hz, n = 7, p > 0.05), the amplitude of GABAAR-mediated sPSCs (median = 7.5 pA, IQR = 6.4–12.0 pA, n = 11 vs. median = 7.1 pA, IQR = 6.6–9.6 pA, n = 7, p > 0.05) and the cumulative amplitude of GABAAR-mediated sPSCs (median = 90.7 pA, IQR = 44.7–360.2 pA, n = 11 vs. median = 95.0 pA, IQR = 48.9–125.4 pA, n = 7, Mann–Whitney U-test, p > 0.05) in the pyramidal neurons of between SOZ and non-SOZ groups (Figures 3C–E). Cumulative GABAAR-mediated sPSCs amplitude distribution from cells depicted in SOZ showed was significantly higher in SOZ compared with non-SOZ group (P < 0.001, Mann–Whitney U-test, Figure 3F).

More depolarized EGABA in seizure the onset zone of focal cortical dysplasia

EGABA reflects the potential at which currents are generated during the voltage ramp in the absence and presence of GABA intersect (Figure 4A). The average EGABA for each neuron measured in the different groups is represented in Figure 4B. The EGABA on pyramidal neurons in the SOZ group (−54.5 ± 6.2 mV, n = 7) was significantly shifted to more positive values compared to that in the control group (−73.0 ± 1.0 mV, n = 7, p < 0.05) and non-SOZ group (−69.2 ± 1.9 mV, n = 6, p < 0.05, Figure 4B). The polarity of GABAergic response is affected by the driving force of GABA. EGABA (−54.5 ± 6.2 mV, n = 7) was more positive than RMP (71.6 ± 2.5 mV, n = 7, Student’s t-test, p < 0.05) in the SOZ group. In contrast, no significant differences were observed between EGABA and RMP in the non-SOZ (−75.2 ± 2.8 mV, n = 6 vs. −69.2 ± 1.9 mV, n = 6) and control groups (−73.6 ± 2.4 mV, n = 7 vs. −73.0 ± 1.0 mV, n = 7). DFGABA was significantly higher in the SOZ group than in the control group (median = 17.85 mV, IQR = 8.43–15.55 mV, n = 7 vs. median = 4.29 mV, IQR = −8.18-4.617 mV, n = 7, p > 0.05 Figure 4B). In contrast, no significant difference was observed in the DFGABA of the non-SOZ group compared to the control group. Application of BUM did not alter EGABA in the control group (−75.1 vs. −71.2 mV), but EGABA shifted to more negative values in the SOZ group (−52.9 vs. −75.0 mV) (Figure 4A).

FIGURE 4

Expression and distribution of K+-Cl in human epileptic focal cortical dysplasia and non-epileptic cortical tissues

In addition to the electrophysiological results indicated significant depolarizing GABAergic signaling in neurons in the SOZ group, we assessed the neuronal expression of NKCC1 and KCC2 in the three groups (Figure 5). As previous studies, NKCC1 showed a wide distribution in a variety of tissues and cell types within and outside the nervous system (). In our study, we also tried to explore the subcellular distribution of NKCC1 using immunofluorescence but found that no significant differences in the subcellular location of NKCC1 were observed across the groups. Strong NKCC1 immunoreactivity was detected in most NeuN-expressing normal-sized neurons in all the groups. Immunostaining for NKCC1 was present in the soma and dense intra-somatic staining (Supplementary Figure 2).

FIGURE 5

Diffuse neuropil staining for KCC2 was observed in the FCD cortical tissue as well as in the control temporal neocortex. The neurons in the SOZ showed that KCC2 was internalized into the cells and that its distribution on the cell membrane was significantly reduced. However, there was no obvious KCC2 cell internalization in the non-SOZ and control groups. Histological analyses revealed cytoplasmic KCC2 accumulation in neurons in the SOZ group, whereas cytoplasmic KCC2 staining was absent in the non-SOZ and control groups (Figures 5A–C). A western blot analysis showed that the expression of KCC2 protein in the SOZ and non-SOZ groups was significantly decreased compared with that in the control group (Figures 5D,E).

Discussion

In this study, we assessed the electrophysiological characteristics and depolarizing synaptic activity of pyramidal neurons in patients with FCD and epilepsy. In particular, we probed the effects of imbalanced function of NKCC1 and KCC2 on GABAergic signaling in pyramidal neurons inside the SOZ, non-SOZ within the EZ of the patients with FCD, and non-epileptic neocortex in patients with MTLE (control). We sought to establish a relationship between macroscopic epileptogenesis and microscopic cell-to-cell communication to better understand the epileptogenic network of FCD through a micro-macro neuro-electrophysiology lens. We observed depolarizing GABAergic signaling in pyramidal neurons located in the SOZ and non-SOZ of the FCD, but not in the control group. Although there is no significant difference between SOZ and non-SOZ in terms of frequency and intensity of depolarizing GABAergic responses at this microscopic level, however, there were more neurons with depolarizing GABAergic responses and higher EGABA in the SOZ than in the non-SOZ, which may explain the macroscopic differences between the SOZ and non-SOZ in patients with FCD. In addition, we revealed that depolarizing GABAergic neurotransmission in FCD patients, which can be reversed by BUM, is related to the imbalanced function of NKCC1 and KCC2 in the SOZ. This is the first comparative study of depolarizing GABAergic signals in the SOZ, non-SOZ, and non-epileptic cortical regions. Our findings provide important evidence of a potential neurocircuit underlying SOZ epileptogenesis and non-SOZ seizure susceptibility. These results also point to a possible mechanism for epileptogenesis in FCD at the cellular and microcircuit levels, highlighting a novel therapeutic avenue for patients with FCD and epilepsy.x

Establishing micro-macro electrophysiological recordings to gain a better understanding of the epileptogenic network of patients with focal cortical dysplasia exhibiting epilepsy

Accurate delineation of the EZ is critical to determining which patients with refractory epilepsy are appropriate candidates for surgical intervention (). Although the EZ remains a theoretical concept, five cortical zones (including the SOZ) related to the EZ are roughly defined in presurgical evaluations (; ). The precise definition of the SOZ has long been thought to accurately delineate the EZ, but it has been found that the EZ is often more extensive than the SOZ, and the precise boundary of the EZ is poorly defined (). Rasmussen et al. proposed that removing the SOZ was necessary but insufficient to achieve lasting seizure-free survival (), which indicates the potential involvement of the non-SOZ within the EZ in epileptogenesis. Currently, epilepsy is considered to be a disease of neural networks (). Successful surgical outcomes depend on the analysis of seizure-generating networks. For a network-based analysis, focusing on regions in the EZ beyond the SOZ to understand the mechanisms of epileptogenesis is crucial (; ; ). In addition, a well-recognized, major clinical problem is that most studies locating the SOZ and EZ mainly emphasize the macroscopic level, with little concern over the microscopic changes involved. Given the markedly different EEG signals between the SOZ and non-SOZ in patients with FCD, we assessed the underlying neurotransmission patterns, particularly the depolarizing GABAergic signals, to uncover potential microscopic distinctions that contribute to the macroscopic differences.

Another challenge in human clinical research remains the acquisition of healthy, non-epileptic brain tissue, which would otherwise not warrant surgical resection in a clinical setting. Here, we chose the temporal neocortex from patients with MTLE as our control group for the following reasons: (1) temporal neocortical tissue lies far from the EZ and is not characterized by any obvious structural aberration (); (2) temporal neocortical tissue has been shown to have the least abnormal transcription of Cl transporters and highest EGABA compared to the subiculum and hippocampal proper in patients with MTLE, which indicates relatively balanced NKCC1 and KCC2 level (); and (3) temporal neocortical tissue is often resected during operations for such patients with epilepsy.

GABAA receptor-mediated depolarization caused by imbalanced function of Na+-K+-2Cl and K+-Cl promotes epileptogenesis in patients with focal cortical dysplasia exhibiting epilepsy

The recruitment of glutamatergic neurons is a fundamental component of seizures (). As 80% of neocortical neurons are excitatory glutamatergic pyramidal neurons (with a higher percentage in CD) (), pyramidal neurons in FCD are maintained in an immature state with hyperexcitable properties in the malformed cortex (). Pathologically interconnected neurons have been hypothesized to gather as novel pathological microdomains, leading to interacting networks that generate hypersynchronous discharges that trigger a seizure (). Previous reports have indicated that the key features of microcircuits captured by microscopic recordings in different brain regions associated with the EZ are significantly different (; ). The heterogeneity of these microcircuits plays an important role in the formation of the macro-networks. Our results demonstrated that the frequency sEPSCs in pyramidal neurons were higher in the patients with FCD than in the non-epileptic cortex. This supports previous findings in animal models of CD (). The increased frequency of sEPSCs in pyramidal neurons is associated with a shorter decay time in the non-SOZ of patients with FCD as compared to that in the non-epileptic cortex, which may reflect a high epileptogenicity in the non-SOZ group. However, recent studies have demonstrated that depolarizing GABA activity, caused by imbalanced function of NKCC1 and KCC2, initiates and propagates hypersynchronous neuronal activity into a larger network (; ). Consistent with the different patterns of NKCC1 and KCC2 during development, GABA initially depolarized immature neurons and controls the early network activity in the developing neocortex (; ). However, Valeeva et al. found a developmental excitatory-to-inhibitory switch in GABA actions on pyramidal neurons from P2–P8 and P9-15 mice in vitro. In contrast, mainly inhibitory GABA actions was shown in the immature hippocampus and neocortex in vivo (). It is that whether traumatic injury might affect results obtained from in vitro preparations is currently highly debated (Zilberter, 2016). Further research is required to clarify whether or not this is the case. Human FCD, which has many similarities to the immature cortex, may result in epileptiform synchronization, paradoxically initiated by GABAA activation and GABAAR-mediated synaptic transmission changes from inhibitory to excitatory effects caused by altered NKCC1 and KCC2 (; ). In our study, we provided direct neuro-electrophysiological evidence of GABAAR-mediated postsynaptic responses, depolarized EGABA in pyramidal neurons at the single-cell level, and corresponding changes in NKCC1 and KCC2 in the SOZ and non-SOZ of patients with FCD exhibiting epilepsy, when compared to those obtained from non-epileptic human temporal neocortex from patients with MTLE. Moreover, we found several differences in GABA activity between the SOZ and non-SOZ groups in the EZ of patients with FCD, highlighting the importance of depolarizing GABA within a seizure network.

Studying microcircuits in the seizure the onset zone and non-seizure the onset zone may help reveal the mechanism underpinning the generation and spread of macroscopic epileptic networks

In our study, consistent with previous studies, we observed that KCC2 expression was downregulated and internalized in the EZ of patients with FCD, especially in the SOZ (; ). Although decreased expression of KCC2 was noted in both the SOZ and non-SOZ groups, internalized KCC2 was only observed in the SOZ group. Impaired KCC2 regulation may represent a risk factor for the emergence of neuropathology. found that heterozygous phosphomimetic variants of KCC2 exhibit altered GABAergic inhibition, increased glutamate/GABA synaptic ratio, and greater susceptibility to seizures. They deduced that dysregulated KCC2 contributed to pathogenesis by controlling the GABAergic developmental sequence in vivo, which has been shown to impair neuronal network formation (). Moreover, normal GABA receptor-mediated inhibition depends on low levels of intracellular Cl, which are modulated by the extrusion of Cl by KCC2. Thus, the loss of KCC2 function results in the neuronal accumulation of Cl, shifting the direction of ion flow through GABA receptors from hyperpolarizing to depolarizing ().

The change of GABA function in the SOZ can strongly affect the microcircuit connection and neuronal network, as well as activate and silence individual neurons. In support of the critical role of KCC2 in postnatal GABAergic inhibition, documented rapid mature neuronal apoptosis induced by KCC2 malfunctioning while immature neurons remained mostly intact. This can be explained by the fact that instead of KCC2, NKCC1 is highly expressed in immature neurons and drives Cl inward. We found that the imbalanced function of NKCC1 and KCC2 in the EZ resulted in depolarization of GABA receptor function and may underpin the hyperexcitability of FCD brain regions. Compared with the control group, SOZ and non-SOZ of patients with FCD showed depolarizing GABA response on pyramidal neurons. Although there were no significant differences in terms of the frequency and intensity of the depolarizing GABA response across the SOZ and non-SOZ groups, fewer neurons with depolarizing GABAergic responses and higher EGABA were shown in the SOZ than in the non-SOZ of FCD patients. The migration of seizures from one side to the other requires the presence of dynamic depolarizing GABA in the network (). Therefore, the non-SOZ may represent a subsequent propagation region involved in FCD epileptogenesis. The non-SOZ, with a higher seizure susceptibility, may represent a potential brain region for the initial propagation of epileptic discharges originating in the SOZ. This is consistent with the macroscopic epileptiform discharges observed on EEG recordings that arise in the SOZ and propagate to the non-SOZ. It has also been suggested that more than one potential SOZ, with different thresholds, may exist in a single EZ (). Although the SOZ with the lowest threshold typically generates seizures, another area in the non-SOZ with the second-lowest threshold would take over to be the new SOZ if the original SOZ has been resected. We speculate that non-SOZ may represent a potential SOZ capable of generating recurrent seizures upon resection of the previous SOZ, which thereby emphasizes the need to remove the entire EZ for seizure-free survival.

Outlooks and limitations

In our study, we focused on the depolarizing GABA synaptic activity caused by the imbalance of NKCC1 and KCC2 and aimed to build a micro-macro neuronal network to determine the relationship between depolarizing GABA and epileptogenesis in FCD. We observed depolarizing GABAergic signaling among pyramidal neurons in both the SOZ and non-SOZ of the patients with FCD, with a higher number of responsive neurons in the SOZ group. Thus, we speculated that abnormal GABAergic activity might influence epileptogenesis in the SOZ group and seizure susceptibility in the non-SOZ group. The microscopic recordings within areas of macroscopic evaluation and definition, that is, SOZ and non-SOZ, also pointed to the importance and potential of mapping epileptic activities at multiple scales. In addition, given the effects of BUM, the maintenance of chloride homeostasis in neurons could represent an alternative avenue for developing ASMs. Previous studies have reported that BUM exerted significant seizure control effects in adult patients with temporal lobe epilepsy (; ). In our study, a BUM application inhibited GABAAR-mediated postsynaptic responses in cortical slices of patients with FCD and epilepsy at the individual cell level. However, the use of BUM as a potential new antiepileptic drug warrant further examination. Future studies should examine BUM derivatives as novel ASMs. In addition to NKCC1, an inhibitor of KCC2 should be explored for its effect on depolarizing GABA responses.

This study had several inevitable limitations. First, although we found the specific NKCC1 inhibitor BUM significantly reduced the depolarizing GABAergic response, it is hard to figure out why BUM functions as a result from functional upregulation of NKCC1 or decreased expression of KCC2 in FCD. To solve this issue, we think that the single-channel recording and the specific and available blocker of KCC2 is in urgent need. Second, it remained difficult to obtain SOZ and non-SOZ from the same patient with FCD to avoid excess injury and protect important functional brain areas during surgery. Finally, the size of our cohort was relatively small, and we did not take a deeper look into the differences across variable FCD subtypes and neuronal subgroups. In the future, a larger cohort of patients should be recruited to assess the potentially different GABAergic functions across FCD subtypes and other types of neurons, such as interneurons.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Xuanwu Hospital, Capital Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

GZ and XFY: supervision and conceptualization. RL: methodology and writing – original draft. YX, HZ, JW, HLL, and LC: writing – review and editing. DL: visualization. TY, XMY, CX, YP, and LZ: provide clinical patient data, tissue specimens, and pathological examination. HHL: review and edit the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (81971202, 81790653, and 81671367).

Acknowledgments

We deeply appreciate the clinical team from the functional neurosurgery department of Xuanwu Hospital of Capital Medical University. We also thank Zhiqian Tong’s technical help in the late stage of this work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2022.954167/full#supplementary-material

Supplementary Figure 1

Action potential properties of pyramidal neurons. (A) The action potential number of pyramidal neurons (PNs) from control, FCD SOZ, and FCD non-SOZ cortex under a stepped current injection lasting 600 ms. N = 16, 19,18 for control and SOZ, non-SOZ groups. (B) The first spike latency of PC from control, FCD SOZ, and FCD non-SOZ under a 300 pA injection. N = 16, 19, 18 for control and SOZ, non-SOZ groups. Data was shown as mean ± SEM.

Supplementary Figure 2

Expression of NKCC1 in neurons from three groups. Double-label immunostaining for NeuN and NKCC1 demonstrated no obvious differences in expression and sub-cellular localization in neurons from SOZ, non-SOZ and control groups. Arrow indicated neurons with intra-somatic expression of NKCC1. Arrowheads indicated neurons with membrane expression of NKCC1. Scale bar represented 20 μm.

References

Summary

Keywords

epilepsy, focal cortical dysplasia, cation-chloride cotransporters, pyramidal neurons, seizure onset zone

Citation

Liu R, Xing Y, Zhang H, Wang J, Lai H, Cheng L, Li D, Yu T, Yan X, Xu C, Piao Y, Zeng L, Loh HH, Zhang G and Yang X (2022) Imbalance between the function of Na+-K+-2Cl and K+-Cl impairs Cl homeostasis in human focal cortical dysplasia. Front. Mol. Neurosci. 15:954167. doi: 10.3389/fnmol.2022.954167

Received

27 May 2022

Accepted

27 September 2022

Published

17 October 2022

Volume

15 - 2022

Edited by

Tobias Engel, Royal College of Surgeons in Ireland, Ireland

Reviewed by

Miao He, Fudan University, China; Misha Zilberter, Gladstone Institutes, United States

Updates

Copyright

*Correspondence: Guojun Zhang, Xiaofeng Yang,

This article was submitted to Brain Disease Mechanisms, a section of the journal Frontiers in Molecular Neuroscience

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics